Sermorelin's FDA History: Why Geref Was Discontinued and What It Means Today
Geref, the only FDA-approved sermorelin product, was voluntarily withdrawn in 2002 for strategic business reasons-not because of new safety issues. Understanding that back-story helps explain why today’s sermorelin is available only through patient-specific compounding pharmacies and what that means for your prescription options.
Sermorelin is a synthetic fragment of growth hormone-releasing hormone (GHRH) that prompts the pituitary gland to release natural growth hormone. Geref, the brand-name injectable sermorelin acetate, received FDA approval in 1997 but left the U.S. market in 2002 when its manufacturer decided sales were too small to justify production. The withdrawal did not stem from safety concerns, so U.S. prescribers may still order patient-specific doses from licensed 503A compounding pharmacies when they determine a patient needs this therapy.
- Geref (sermorelin acetate) was approved by the FDA on April 7, 1997 for children with growth hormone deficiency (FDA approval letter).
- The manufacturer ceased U.S. distribution in 2002 citing “limited commercial demand,” not safety issues, and the product’s New Drug Application (NDA 20-604) remains listed as discontinued, not withdrawn for cause (fda.gov).
- No FDA-approved sermorelin products are sold today, so prescriptions are filled only by 503A compounding pharmacies on an individual-patient basis.
- Compounded sermorelin is not FDA-approved and is prepared under state pharmacy law after a licensed provider writes a prescription.
- Adults exploring sermorelin from Rx.com must complete an online medical visit; a provider decides if the benefits outweigh the risks for that individual.
What sermorelin is and how it works
Sermorelin is a 29-amino-acid analog of endogenous growth hormone-releasing hormone. By binding GHRH receptors on the pituitary, it triggers the gland to release pulsatile bursts of the body’s own growth hormone, which then promotes production of insulin-like growth factor 1 (IGF-1) in the liver. Because sermorelin stimulates a regulated physiologic pathway rather than supplying external growth hormone, its effect tapers when natural negative feedback mechanisms kick in.
Definition: Sermorelin is a synthetic peptide that mimics the first 29 amino acids of human GHRH, previously sold under the brand Geref for pediatric growth hormone deficiency.
Unlike recombinant human growth hormone injections, sermorelin is not currently marketed as an FDA-approved drug. Any sermorelin you receive today is compounded for you individually once a prescriber writes an order and must be labeled “not FDA-approved.” For a deeper dive into the legal landscape, see our legal status overview.
Key FDA milestones for sermorelin
The FDA approved Geref in 1997 based on randomized pediatric data showing increased growth velocity in children with documented growth hormone deficiency. Below is a concise timeline of the regulatory history.
| Date | Event | Significance |
|---|---|---|
| April 7, 1997 | NDA 20-604 approved | Geref (sermorelin acetate) receives FDA approval for pediatric use |
| 1998-2001 | Post-marketing surveillance | No new safety signals beyond mild injection-site reactions reported to FDA |
| Summer 2002 | Manufacturer notifies FDA of discontinuation | Company cites low demand and strategic focus elsewhere |
| October 21, 2002 | Drug removed from distribution | NDA remains active but listed as “discontinued,” allowing future return |
| 2003-present | No further FDA submissions | No brand or generic applicant has sought approval since |
Why Geref was discontinued
Geref’s exit was driven by economics, not by an FDA safety withdrawal. The product never reached blockbuster status and faced competition from multiple recombinant growth hormone brands that physicians were already comfortable using. According to the discontinuation notice filed with the FDA (fda.gov), the manufacturer determined that the sales volume did not justify the costs of continued production, cold-chain distribution, and post-marketing obligations.
Because the withdrawal was voluntary and “not for reasons of safety or effectiveness,” the FDA did not remove sermorelin from the Orange Book for cause. The agency continues to list it as “Discontinued,” meaning the NDA could, in theory, be reactivated by a sponsor at any time without starting from scratch.
Current legal status of compounded sermorelin
With no FDA-approved product on the market, U.S. prescribers who believe a patient needs sermorelin must rely on 503A compounding pharmacies. Under federal law, a 503A pharmacy may compound a peptide that is identical to an approved drug only when the approved product is unavailable or the prescriber determines the patient requires a variation. Because Geref is unavailable, pharmacies can legally prepare sermorelin acetate once they receive a valid prescription.
However, compounded peptides are not FDA-approved and do not undergo pre-market manufacturing inspections. Quality, potency, and sterility depend on the individual pharmacy’s compliance with USP 797 sterile compounding standards and state board oversight. For tips on vetting a pharmacy and a prescriber, read our guide to online peptide prescriptions.
💡 Not the same as brand-name approval
Even though compounded sermorelin uses a USP-grade active pharmaceutical ingredient, the finished product is not the same as the discontinued brand. Pharmacy compounding is exempt from FDA’s full New Drug Application process.
If your prescriber believes sermorelin could be helpful, they may send a prescription to a licensed compounding pharmacy, or you can complete an online consultation to see if sermorelin from Rx.com is appropriate for you.
How prescriptions are written and filled today
Getting sermorelin starts with an evaluation by a licensed U.S. provider who can legally prescribe controlled substances in your state. The visit may be in person or via telehealth. Expect a detailed health history and, often, lab work that checks baseline IGF-1, thyroid function, and other markers that could influence growth hormone pathways.
Ordering through Rx.com: Adults complete a secure online intake that is reviewed by a licensed prescriber. If sermorelin is appropriate, the provider writes an individualized prescription that is transmitted to a U.S. compounding pharmacy. The pharmacy prepares and ships the medication after verifying the order-because each vial is made for one patient, there is no off-the-shelf inventory.
For a step-by-step walkthrough, see our online prescription guide. If you already have a prescription from your own provider, you can still compare compounding options or ask about filling it through sermorelin from Rx.com.
Safety profile and potential side effects
Clinical trials and post-marketing surveillance of Geref found a generally mild side-effect profile. The most common reactions were transient injection-site redness, mild headache, and flushing. In rare cases, children experienced nausea or vomiting, which resolved without intervention (DailyMed label).
Adult safety data are limited. Because the FDA-approved indication was pediatric, published adult studies are smaller and often exploratory. Reported adverse events in adult trials include mild peripheral edema and joint stiffness. Serious events such as cancer growth or severe glucose intolerance have not been linked conclusively, but long-term data are sparse.
| Therapy | FDA status | Approved indications | Common side effects |
|---|---|---|---|
| Recombinant growth hormone (somatropin) | FDA-approved | Pediatric & adult GH deficiency, Turner syndrome, others | Joint pain, edema, carpal tunnel, headache |
| Sermorelin (Geref, discontinued) | FDA-approved 1997; discontinued 2002 | Pediatric GH deficiency | Injection-site redness, headache, flushing |
| Compounded sermorelin | Not FDA-approved | Prescriber-determined off-label uses | Expected similar to Geref, data limited |
Drug interactions: Concurrent use with glucocorticoids may blunt sermorelin’s effect. Thyroid dysfunction can also interfere with growth hormone pathways, so providers often check TSH and free T4 before and during therapy.
Should you consider compounded sermorelin?
Is compounded sermorelin a reasonable next step for you?
Check the column that best matches your situation:
✅ Good candidate
- Documented low IGF-1 or diagnosed growth hormone deficiency
- Normal thyroid and cortisol levels or well-controlled replacement therapy
- No active malignancy in the past five years
- Willingness to self-inject and to complete regular lab monitoring
🏥 See your doctor first
- History of active cancer or unexplained elevated IGF-1
- Uncontrolled diabetes or proliferative diabetic retinopathy
- Severe untreated sleep apnea
- Pregnancy or breastfeeding
- Use of systemic glucocorticoids without medical supervision
🚨 When to Contact Your Healthcare Provider
🚨 When to Contact Your Healthcare Provider
Contact your doctor immediately if you experience any of the following while using compounded sermorelin:
- Severe swelling of hands or feet: may signal fluid retention that needs dose adjustment
- Numbness or tingling in the wrists: possible carpal tunnel syndrome from elevated GH
- Persistent headache with blurred vision: could indicate intracranial pressure changes
- New lump or unexplained pain: growth hormone can theoretically stimulate tumor growth
- Rapid changes in blood sugar: monitor if you have diabetes or pre-diabetes
- Shortness of breath when lying down: fluid overload can worsen heart failure
- Severe joint pain that limits movement: may require discontinuation
- Signs of an allergic reaction such as rash, itching, or swelling at the face or throat
Frequently Asked Questions
Scientific References
Why is there no FDA-approved sermorelin on the market today?
The only approved product, Geref, was discontinued by its manufacturer in 2002 due to limited sales. No company has since filed to reintroduce or replace it, so the market relies on pharmacy compounding.
Is compounded sermorelin legal in all 50 states?
Yes, a licensed provider may prescribe compounded sermorelin nationwide, but each state’s pharmacy board regulates how pharmacies prepare and dispense it. Some states require the pharmacy to be licensed locally before shipping into the state.
Does compounded sermorelin need prior authorization from insurance?
Most commercial insurers do not cover compounded medications, and compounded sermorelin typically requires cash pay. Patients often compare out-of-pocket costs among pharmacies or explore programs like sermorelin from Rx.com.
Can adults use sermorelin for anti-aging?
Some clinicians explore off-label adult use, but the FDA never evaluated sermorelin for anti-aging, muscle gain, or athletic performance. Benefits and long-term safety for those goals remain unproven, so discuss realistic expectations with your provider.
How is sermorelin stored and handled?
Compounded sermorelin is shipped refrigerated. Pharmacies include precise storage instructions-typically refrigeration until first use and a limited in-use period. Follow the label exactly and never freeze the product.
Is sermorelin the same as human growth hormone (HGH)?
No. HGH is the end hormone itself, whereas sermorelin stimulates your pituitary to release endogenous growth hormone. This indirect mechanism may reduce the risk of excessive hormone levels.
Can I switch from recombinant growth hormone to sermorelin?
Possibly, but the clinical rationale differs. Do not stop prescribed HGH without medical guidance. Your provider will review lab values, symptoms, and treatment goals before recommending any transition.
What labs are monitored during therapy?
Common tests include IGF-1, fasting glucose, thyroid function, and a comprehensive metabolic panel. Your provider sets the schedule, often every three to six months.
